Results 121 to 130 of about 1,582,904 (250)

Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency

Life Science Alliance
The NLRP3 inflammasome drives various diseases. Here, we describe novel potent and selective NLRP3-targeted inhibitors to bolster pharmacological studies and development of NLRP3-targeted therapies.
Lieselotte Vande Walle, Madhukar Said, Oonagh Paerewijck, Arinna Bertoni, Marco Gattorno, Bruno Linclau, Mohamed Lamkanfi   +6 more
doaj   +1 more source

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X, Varnado OJ, Bae JP, Jiang D, Liu D   +4 more
core  

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use.
Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang, Cheng‐Jung Ho, Chung‐Hwan Chen, Li‐Nien Chien   +5 more
wiley   +1 more source

The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport, Glucose Transporter Translocation, and Dephosphorylation In Insulin-Resistant Rat Adipocytes In Vitro [PDF]

, 1993
Wied, Susanne, Müller, Günter
core   +1 more source

Signaling and sites of interaction for RX-871024 and sulfonylurea in the stimulation of insulin release

, 1998
The objective of this study was to compare effects of RX-871024, a compound with imidazoline structure, and the sulfonylurea glibenclamide, representatives of two groups of ATP-dependent potassium channel (KATP) blockers, on insulin secretion and ...
Berggren, PO, Claes-Göran Östenson, Zaitsev, SV, Zaitsev, Sergei V., Efendic, S, Efanova, IB, Berggren, Per-Olof, Suad Efendić, Ioulia B. Efanova, Alexandre M. Efanov, Östenson, CG, Zhu, SS, Sergei V. Zaitsev, Efanova, Ioulia B., Zhu, Shunsheng, Efanov, Alexandre M., Efanov, AM, Shunsheng Zhu, Efendić, Suad, Östenson, Claes-Göran, Per-Olof Berggren   +20 more
core   +1 more source

Discontinuation of Glucagon‐Like Peptide‐1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real‐World, Database Study

Journal of Evidence-Based Medicine, EarlyView.
ABSTRACT Objective Although concerns have been raised that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may increase the risk of bowel obstruction or ileus, evidence remains inconclusive. In this context of uncertainty, we examined the frequency and determinants of GLP‐1RA discontinuation after hospitalization for bowel obstruction/ileus ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study

, 2020
Background: Due to several limitations in the study designs of sulfonylurea pharmacogenomics studies, we investigated the clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients.
Vethakkan, Shireene Ratna, Hussein, Zanariah, Huri, Hasniza Zaman, Loganadan, Navin Kumar   +3 more
core  

Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury

, 2017
OBJECTIVES: Cerebral edema is a key poor prognosticator in traumatic brain injury. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies.
Chang, Chung-Chou H, Wallisch, Jessica S, Ruchira M. Jha, Ava M. Puccio, Patrick M. Kochanek, Keri L. Janesko-Feldman, Bradley J. Molyneaux, Sherry Hsiang-Yi Chou, Chung-Chou H. Chang, David O. Okonkwo, Jha, Ruchira M, Jessica S. Wallisch, Shutter, Lori A, Lori A. Shutter, Janesko-Feldman, Keri L, Chou, Sherry Hsiang-Yi, Molyneaux, Bradley J, Okonkwo, David O, Samuel M. Poloyac, Zusman, Benjamin E, Benjamin E. Zusman, Puccio, Ava M, Kochanek, Patrick M, Poloyac, Samuel M   +23 more
core   +1 more source

Burden and Risk Factors of CGM‐Detected Hypoglycemia in Older Adults With Type 2 Diabetes

Journal of the American Geriatrics Society, EarlyView.
Among older adults with diabetes using insulin or sulfonylureas, the median time spent in hypoglycemia was 3.4% and ~66% of participants exceeded the target of < 1% time with CGM glucose < 70 mg/dL. ABSTRACT Background Comprehensive data on the burden of biochemical hypoglycemia in older adults with type 2 diabetes are lacking.
Michael Fang, Natalie Rula Daya, Yein Jeon, Justin B. Echouffo‐Tcheugui, B. Gwen Windham, Scott Zeger, Elizabeth Selvin   +6 more
wiley   +1 more source